Navigation Links
Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D

ROCKVILLE, Md. and BEIJING, Jan. 10, 2012 /PRNewswire-USNewswire/ -- The global fight against the tuberculosis epidemic receives a boost today as Aeras and the China National Biotec Group (CNBG) announce that they have reached final agreement to jointly develop new tuberculosis (TB) vaccines. The agreement between the leading non-profit developer of TB vaccine candidates and the largest biotechnology corporation in China signals a commitment by both to engage and strengthen the role of China in the fight against one of the world's deadliest infectious disease killers.

Xiaoming Yang, President of CNBG, said of the agreement: "CNBG has a great deal of expertise and energy to invest in this partnership. Not only is TB a public health crisis of the developing world, it is also a priority health issue here in China. We look forward to working with our counterparts at Aeras to develop new TB vaccines that will help stop tuberculosis in all corners of the world."

Multiple research institutes operating under the umbrella of CNBG will engage with Aeras on a strategy focused on the joint development, manufacturing and distribution of affordable new TB vaccines for use globally. The agreement spans all aspects of TB vaccine development – from vaccine discovery to pre-clinical research to clinical research to manufacturing – and positions CNBG as a major emerging player in the TB vaccine field.

Bacille Calmette-Guerin (BCG), the only currently-licensed TB vaccine, does not prevent pulmonary TB, the most common form of the disease. As part of this collaboration, Aeras will license its recombinant BCG (rBCG) platform – which aims to improve upon the current TB vaccine – and other technologies to CNBG. The groups will jointly develop novel TB vaccines using the rBCG platform and other technologies provided by Aeras or CNBG's research institutes. A variety of candidate booster vaccines will be engineered to match the new constructs with a goal to create more efficacious and longer-lasting protection against TB disease.

A keystone of this broad collaboration is the implementation of joint product development teams to develop and execute comprehensive plans for both the research and clinical development of TB vaccines and the design, construction and validation of a vaccine process development and manufacturing facility in China, which will receive financial support and technical expertise provided by Aeras.

"The synergy created by bringing together our scientific and manufacturing expertise could have a substantial impact on efforts to advance innovative candidates in TB vaccine development," said Jim Connolly, President and CEO of Aeras. "We look forward to working with the largest biotech corporation in a country with the skills, resources and TB disease burden to play a major role in overcoming the complex challenges of TB vaccine R&D."

TB is a major public health priority in China, where there are more than one million new TB cases every year. Globally, the TB epidemic is responsible for the deaths of 1.4 million people annually. 

About Aeras
Aeras ( is a non-profit product development organization dedicated to the development of effective TB vaccines and biologics to prevent TB across all age groups in an affordable and sustainable manner. Aeras utilizes its broad capabilities and technologies in collaboration with numerous partners and stakeholders to support the development of vaccines and other biopharmaceuticals to address TB and other significant public health needs of underserved populations. Aeras has invented or supported the development of six TB vaccine candidates to date, five of which are currently undergoing Phase I and Phase II clinical testing in Africa, Asia and North America. Aeras receives funding from the Bill & Melinda Gates Foundation, other private foundations and various governments. Aeras is based in Rockville, Maryland, USA – where it operates a state-of-the-art manufacturing and laboratory facility – and Cape Town, South Africa.

About CNBG
CNBG ( is a company limited by shares, the controlling shareholder of which is China's National Pharmaceutical Corporation (Sinopharm). CNBG has 10 subsidiaries and is the largest biotech corporation in China engaged in the research and development, manufacturing and marketing of biological products. CNBG manufactures more than 200 kinds of biological products (with approximately 100 GMP product lines) for prophylactic, therapeutic and diagnostic use, including all the vaccines in China's EPI programme, and maintains an 80% share of the public sector in China. In 2010, the annual output of CNBG reached 730 million doses, and it maintains one of the broadest portfolios of vaccine products in the world.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
6. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
7. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
10. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):